Prior studies have implicated MYC signaling and downstream activation of ER stress as a mechanism for sensitivity to proteasome inhibitors in Kras/Tp53 mutant pancreatic cancers with Smarcb1 deficiency (Genovese et al., 2017; Moreau et al., 2016). This evidence concerns the gene TP53 and pancreatic neoplasm.